Boris Gorovits
About Boris Gorovits
Boris Gorovits serves as Vice President at Sana Biotechnology, Inc., where he leads efforts in in vitro pharmacology and biomarker discovery. He has a strong background in biochemistry and enzymology, with extensive experience at Pfizer and contributions to numerous scientific publications.
Current Role at Sana Biotechnology
Boris Gorovits serves as Vice President at Sana Biotechnology, Inc. since 2021. He is based in Cambridge, Massachusetts, where he leads a group focused on in vitro pharmacology, biomarker discovery, and bioanalysis of advanced stage modalities. His role involves collaborating with both internal and external partners to support discovery and later stage studies. He provides strategic leadership for both regulated and non-regulated studies, contributing to the company's mission in biotherapeutics.
Previous Experience at Pfizer
Boris Gorovits has extensive experience at Pfizer, where he held multiple roles over a span of 14 years. He worked as a Senior Research Scientist from 2000 to 2002, then progressed to Director from 2006 to 2015, and later served as Senior Director from 2015 to 2020. His tenure at Pfizer involved significant contributions to research and development in the pharmaceutical sector.
Education and Academic Background
Boris Gorovits obtained both his M.S. and Ph.D. in Enzymology and Biochemistry from Lomonosov Moscow State University. He studied from 1981 to 1986 for his M.S. and continued his education from 1986 to 1990 for his Ph.D. This academic foundation has supported his extensive career in biotherapeutics and bioanalysis.
Research Contributions and Publications
Boris Gorovits has co-authored several publications in the field of biotherapeutics. Notably, he contributed to a paper on calibration curves in quantitative ligand binding assays published in the AAPS Journal in 2017. He also authored a publication on the immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics in BioDrugs in 2019 and contributed to a publication on bioanalysis of Adeno-Associated Virus Gene Therapy Therapeutics in Bioanalysis in 2019. His record includes over 50 manuscripts and book chapters.
Professional Affiliations and Leadership Roles
Boris Gorovits is an active member of the American Association of Pharmaceutical Scientists (AAPS), with over 20 years of involvement. His contributions include leadership roles in meeting programming and biotech sections. He has participated in advancing global science through publications and presentations at national and international conferences.